Apotheca to Fight Opioid Addiction Through Cannabinoid Pain Alleviation Medical Device
Seattle, WA. , May 08, 2018 (GLOBE NEWSWIRE) -- Cannabis Leaf (OTC PINK: PCFP), a developer of cutting-edge medical
products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry, announces today that
the Company has secured the IP rights for Pain Patch, Apotheca Biosciences’ pain alleviation technology.
Apotheca has been developing Pain-Patch using CannaDERME transdermal delivery and state-of-the art smart device technologies for
relieving various pains. Apotheca has formulated cannabidiol-based Pain-Patch for proof-of-concept studies. The company has now
secured the two patent rights for this novel device which encompasses CannaDERME™ transdermal formulation and Pain-patch medical
device technologies.
- Cannabidiol is one of the key cannabinoid constituents in Hemp Plant. CBD is non-psychoactive and safe compound with a wide
range of therapeutic applications, including the treatment of neural disorders and clinical studies have suggested a wide range
of possible therapeutic effects of cannabidiol on several conditions.
- The Pain-Patch has transcutaneous cannabinoid penetration technology coupled with thermosensitive nano-emulsion for sustained
release of compounds for longer time. The device delivers therapeutic doses to brain via brain stem for whole-body effect.
- The goal of these patches are to produce a pain-patch with a small footprint for easy concealment, a strong formula to
counteract the decreased quality of life for individuals who suffer with systemic pain, a long shelf-life and the use of
non-toxic and non-abrasive components to create the most comfortable and effective patch on the market using this
technology.
- Apotheca is partnering up with pain management physician and opioid addiction centers groups for conducting clinical studies
using Pain-Patch for various kinds of chronic pain and addiction.
“We shared our pain-patch with leading pain doctors in the region and they were all excited”; Preliminary studies on pain-patch
shows excellent results” said Bobban Subhadra, M.S., Ph.D, Chief Operating Officer of Apotheca. “We are securing the IP rights and
partnering with more pain doctors to get their valuable clinical feedback” he added.
About Apotheca Biosciences Inc.
Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for
the healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery
technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its
technologies to the world’s aging population.
To request further information about Apotheca, please email info@apothecabio.com, or visit its website at
http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the
introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions,
and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and
uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that
we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect,"
"believe," and similar expressions generally identify forward-looking statements. These statements reflect our current
expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and
changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may
be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain.
Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties
including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated
actions.
Contact: Jason Sakowski Media Contact : 206.430.6250 Apotheca Biosciences http://www.apothecabiosciences.com info@apothecabio.com Twitter - @apotheca Facebook - apotheca
